Citation Impact
Citing Papers
Origins and evolution of the Western diet: health implications for the 21st century1,2
2005 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
2016
Optical control of insulin release using a photoswitchable sulfonylurea
2014
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
2014
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Catalytic Functionalization of C(sp2)H and C(sp3)H Bonds by Using Bidentate Directing Groups
2013 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
2018
Enantioselective, intermolecular benzylic C–H amination catalysed by an engineered iron-haem enzyme
2017 StandoutNobel
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β
2020
Diabetes Mellitus and Heart Failure
2017
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
2018
CH Bond Functionalization: Emerging Synthetic Tools for Natural Products and Pharmaceuticals
2012 Standout
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
The changing landscape of atherosclerosis
2021 StandoutNature
Disruption of an Evolutionarily Novel Synaptic Expression Pattern in Autism
2016 StandoutNobel
Synthesis of Extended π‐Systems through C–H Activation
2014 Standout
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments
2015
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
Type 2 diabetes
2017 Standout
Epicardial adipose tissue in contemporary cardiology
2022
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
The potential for renoprotection with incretin-based drugs
2014
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Diabetes Mellitus and Heart Failure
2017
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
2016
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
G‐protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal
2004 StandoutNobel
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Lanopylins A1, B1, A2 and B2, Novel Lanosterol Synthase Inhibitors from Streptomyces sp. K99-5041
2003 StandoutNobel
Cardio-renal protection with empagliflozin
2016
The Cross‐Dehydrogenative Coupling of CH Bonds: A Versatile Strategy for CC Bond Formations
2013 Standout
Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance
2000
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
2004
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
2017
Pavlovian psychopharmacology: The associative basis of tolerance.
2000
Asymmetric Synthesis of 3‐Amino‐δ‐lactams and Benzo[a]quinolizidines by Catalytic Cyclization Reactions Involving Azlactones
2009
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
3d Transition Metals for C–H Activation
2018 Standout
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
2018
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Oxidative Coupling between Two Hydrocarbons: An Update of Recent C–H Functionalizations
2015 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Development of Eating Behaviors Among Children and Adolescents
1998 Standout
Mild metal-catalyzed C–H activation: examples and concepts
2016 Standout
Cardiovascular Biology of the Incretin System
2012
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Some like it hot: A temporal analysis of hedonic responses to chili pepper
1982
The nature and acquisition of a preference for chili pepper by humans
1980
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
2017
Diabetic Cardiomyopathy
2018 Standout
Synthetic approaches to the 2011 new drugs
2013
Dipeptidyl Peptidase IV and Its Inhibitors: Therapeutics for Type 2 Diabetes and What Else?
2013
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Palladium-Catalyzed Intermolecular Directed C−H Amidation of Aromatic Ketones
2011
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
The cultural niche: Why social learning is essential for human adaptation
2011 Standout
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
2016
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
2018
Sodium‐glucose co‐transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials
2016
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia
2013
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
2019
TRP ION CHANNELS AND TEMPERATURE SENSATION
2006 StandoutNobel
Complete Field Guide to Asymmetric BINOL-Phosphate Derived Brønsted Acid and Metal Catalysis: History and Classification by Mode of Activation; Brønsted Acidity, Hydrogen Bonding, Ion Pairing, and Metal Phosphates
2014 Standout
Fourth universal definition of myocardial infarction (2018)
2018 Standout
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Emerging Targets in Photopharmacology
2016 StandoutNobel
Transition Metal-Catalyzed C–H Amination: Scope, Mechanism, and Applications
2017 Standout
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Funktionalisierung von C‐H‐Bindungen: neue Synthesemethoden für Naturstoffe und Pharmazeutika
2012
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
Enantioselective Total Synthesis of Nigelladine A via Late-Stage C–H Oxidation Enabled by an Engineered P450 Enzyme
2017 StandoutNobel
Works of Michael Mark being referenced
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
2014
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
2012
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
2011
Empagliflozin, a novel potent and selective SGLT‐2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin‐induced diabetic rats, a model of type 1 diabetes mellitus
2012
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis
2013
The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats
2012
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
2015
Repaglinide and Related Hypoglycemic Benzoic Acid Derivatives
1998
Conditioned opponent responses in human tolerance to caffeine
1984
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
2016
The role of desensitization to capsaicin in chili pepper ingestion and preference
1981
Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo
1997
Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
2016
8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
2007